**Shares of clinical-stage immune-oncology co Imugene
rise as much as 14.6% to A$0.055; biggest intraday pct gain since Sept. 2
** U.S. FDA gives orphan drug status to co's VAXINA treatment, aimed at treating cholangiocarcinoma, a form of bile tract cancer
** FDA grants orphan drug status to promote drug development for rare diseases affecting fewer than 200,000 people in the U.S.
** Co says orphan status gives it range of incentives including tax credits, potential grant funding and 7-year market exclusivity
** About 56.7 mln shares change hands vs 30-day avg volume of about 23.7 mln shares
**Stock down 54.5% YTD
(Reporting by Nikita Jino in Bengaluru)
((Nikita.Jino@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.